Site Management/Investigator Payments Featured Articles

1. How To Lead A Moonshot Collaboration: Lessons From Over A Decade Of Competitors Working Together 2/3/2026

   TransCelerate BioPharma's Andy Lee and Janice Change share the lessons they learned bringing disparate voices together for a united purpose.

2. The U.S. Trial Advantage Is Eroding 1/30/2026

   Once the go-to location for trials, the U.S. is now seeing competition from APAC, driven by political, economic, and workforce pressures domestically and rapid growth abroad.

3. Too Little Info, Too Much Time Wasted: Feasibility Challenges For Sites 1/27/2026

   Incomplete protocols, lengthy sponsor decision timelines, and uncompensated work plague clinical research sites. Learn why these issues exist and how to address them alongside experts from SCRS and Tufts CSDD.

4. What CROs Do Right Isn't Always Obvious To Research Sites 1/26/2026

   CROs are doing many things right. But it's when that right thing is understood — not just executed — that the impact becomes far greater than compliance alone.

5. How Gilead Includes Patients Most Affected By HIV In Its PrEP Trials 1/26/2026

   VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.

6. When Clinical Trials Don't Stop For War 1/23/2026

   When war halted clinical trials in Ukraine, sites adapted instead of shutting down. Dr. Anna Titkova explains how patients, investigators, and sponsors kept research moving when conditions were anything but stable.

7. Endpoints, Procedures, And Deviations Are On The Rise — Why? 1/20/2026

   SCRS Chief Site Success Officer Jimmy Bechtel, MBA, and Tufts CSDD Executive Director Ken Getz, MBA, discuss why they're on the rise explore ways to address, and even accept, them. 

8. Site Management And Oversight Become Must-Haves For Successful Sites 1/15/2026

   Site management and site oversight are often used interchangeably in clinical research, but they mean different things. Explore their roles and importance in ensuring successful sites and trials.

9. Could Moving To This Swiss Life Sciences Hub Be In Your Company's Future? 1/15/2026

   Basel Area Business & Innovation CEO Christof Klöpper discusses how the Basel Area Life Sciences Supercluster supports discovery through commercialization.

10. The Case For Research-Naive PIs 1/9/2026

    Carrie Lewis, executive director, clinical program optimization, at Keenova (formerly Endo) explains why research-naive PIs may improve trial quality, challenge assumptions about ROI, and help fix a shrinking investigator pipeline.